Intelligent Bio Solutions (INBS) (NASDAQ:INBS) has announced plans to upgrade its drug screening reader, the Intelligent Fingerprinting Drug Screening System, to support multiple languages across North and South America, Europe, Asia Pacific, and the Middle East, making it available to more than four billion people worldwide.
According to INBS, the update will enhance usability, ensure greater efficiency in safety-critical industries, and address the growing demand for workplace drug testing solutions—a market projected to reach $8 billion globally by 2030.
Harry Simeonidis, president and CEO of INBS, stated, “As we expand our global footprint, it is essential that our solutions are accessible and adaptable to meet the needs of an increasingly diverse customer base. This multilingual upgrade to our drug screening reader represents as significant step forward in our mission to deliver accessible testing solutions. Importantly, this update will open up opportunities for us to enter new international markets and customer segments, supporting revenue growth.”
